Curient, Approval Granted for Phase 2 Clinical Trial Plan of COVID-19 Treatment Candidate Telacebec

[Asia Economy Reporter Minji Lee] Curient announced on the 24th that it has received approval from the South African Health Products Regulatory Authority for the Phase 2 clinical trial plan of its COVID-19 treatment candidate, Telacebec.

The company stated, "We plan to verify the efficacy, pharmacokinetics, safety, and biomarker changes of Telacebec when administered to patients with COVID-19 disease."